United States · evidence ledger
Clinical Evidence Map
A structured view of published and ongoing research on ibogaine and noribogaine: what a study design can show, what it cannot, and where safety and regulatory uncertainty still matter.
Research status is not treatment approval.
Appraisal rule
Separate reported outcomes from conclusions a study design cannot support.
Evidence taxonomy
Start with the study architecture.
Evidence about ibogaine can come from randomized controlled trials, single-arm investigational new drug cohorts, case series, and registry data. These categories answer different questions; none should be treated as interchangeable proof of clinical benefit or safety.
For the broader policy context that surrounds this map, the U.S. policy and research tracker distinguishes investigational research from approved treatment. The research question, comparator, eligibility criteria, outcome timing, and adverse-event collection plan determine what an individual result can credibly mean.
Comparative trials
IND cohorts
Case series
Registries
Highest control
Randomized controlled trials
Allocation and a comparator can reduce some sources of bias. Their usefulness still depends on masking, follow-up, prespecified endpoints, and whether the sample reflects the population at issue.
Early signal
Single-arm IND cohorts
Prospective protocols can standardize screening and monitoring, but without a control group they cannot reliably separate treatment effects from selection, expectation, or natural change.
Descriptive record
Case series
These reports can identify hypotheses and unusual harms. They are particularly vulnerable to incomplete reporting, selective inclusion, and uncertain denominator data.
Practice signal
Registry data
Registries may show patterns across settings, but completeness, data definitions, follow-up loss, and independent adjudication determine how interpretable those patterns are.
Completed and ongoing work
Use a trial record as a map, not a verdict.
For completed research, a transparent appraisal records the methodology, enrolled sample, primary and secondary endpoints, follow-up period, results, limitations, and adverse-event reporting. Published findings should be read alongside the protocol when available, particularly where outcomes changed, data are missing, or follow-up is brief.
For active or not-yet-reported work, an NCT entry on ClinicalTrials.gov can identify the stated status, sponsor, eligibility criteria, planned outcomes, and locations. Registration is useful for accountability, but a listing does not establish efficacy, safety, completion, or an available treatment option.
Method
Randomized, single-arm, retrospective, or descriptive
Check comparator, allocation, masking, and protocol control.
Sample
Enrolled, treated, analyzed, and retained participants
Check exclusions, dropouts, and whether the cohort is representative.
Outcomes
Prespecified endpoint and timing of assessment
Check whether results match the registered plan and duration of follow-up.
“A promising signal and a settled conclusion are not the same kind of evidence.”
International studies may still inform U.S. safety interpretation, especially when they describe monitoring, exclusion criteria, cardiac screening, or serious adverse events. Yet site practices, co-exposures, referral patterns, and emergency resources may differ materially from a U.S. investigational setting.
Safety signal ledger
Serious risks belong in every evidence reading.
Ibogaine has been associated in published literature with cardiac conduction concerns, including QTc prolongation and arrhythmia, as well as seizure and reported deaths in uncontrolled settings. The FDA drug safety information framework explains why serious adverse events, interactions, monitoring, and reporting quality require careful assessment rather than casual comparison across studies.
Ibogaine is listed by the U.S. Drug Enforcement Administration as a Schedule I controlled substance; its drug scheduling overview provides the governing federal classification context. A classification or a research protocol does not replace patient-specific medical or legal advice.
- QTcCheck baseline and follow-up electrocardiography, thresholds, and the handling of prolonged values.
- ArrhythmiaLook for adjudication, monitoring duration, co-medications, and timing relative to dosing.
- SeizureAsk whether neurologic events were prespecified, actively collected, and described with context.
- MortalityConfirm denominator, follow-up window, attribution process, and whether deaths outside the site were sought.
Reader checklist
Questions that make evidence quality visible.
- Was the study question clear, and was the design capable of answering it?
- Who was eligible, who was excluded, and how many participants completed each stage?
- Were endpoints prespecified, measured consistently, and reported at the planned time points?
- Was there a comparator group, and if not, what alternative explanations remain plausible?
- How were adverse events collected, classified, followed, and independently reviewed?
- Were co-occurring medications, substance use, cardiac risk factors, and monitoring procedures described?
- Does the conclusion stay within the limits of the sample size, design, and duration of follow-up?
This framework is for transparent appraisal, not clinical recommendation. People comparing claims about outcomes can also examine how reported ibogaine success rates depend on definitions, follow-up, and who was measured.
Research questions
What this map can clarify.
Evidence gaps matter to regulators, researchers, advocates, families, and people trying to distinguish an investigational claim from a reliable conclusion.
Does an ongoing NCT record mean the intervention is established?
No. Registration documents a planned or active study and its stated parameters. It does not by itself verify completion, results, regulatory approval, or appropriate access outside research.
Why are international reports included in a U.S. evidence map?
They may provide safety context and methodological lessons, but differences in settings, participants, screening, and emergency capacity can limit direct transfer to U.S. interpretation.
Where should safety claims be examined most closely?
Claims should be compared with the study’s eligibility rules, cardiac monitoring, adverse-event definitions, follow-up window, and missing-data handling. A discussion of long-term side-effect questions is most useful when those limits remain visible.
What information is outside the scope of this page?
This page does not recommend treatment, assess individual suitability, or validate access claims. Questions about locations should be separated from evidence review; ibogaine treatment location claims do not change a study’s design or regulatory status.
Continue tracking carefully
Keep policy, research, and access claims separate.
For context beyond clinical-study appraisal, compare personal accounts on ibogaine trip reports with formal evidence, and distinguish promotional claims from the policy questions addressed by the resource’s research tools.
Interpretation boundary
Evidence review is not a pathway to treatment.
Claims relating ibogaine to trauma symptoms require particularly careful appraisal of diagnosis, outcome measurement, duration, co-interventions, and safety procedures. The separate discussion of ibogaine and PTSD treatment claims should be read as a question of evidence quality rather than a recommendation.
Cost and destination information can also create an appearance of settled legitimacy that research does not establish. Commercial comparisons such as Costa Rica ibogaine clinic cost information belong to a different category from a registered trial, a published outcome, or a U.S. regulatory determination.
For a concise explanation of the organization’s evidence-first approach and independence, see the approach behind Open Field 30. This map remains focused on methods, reported signals, and the unanswered questions that deserve continued scrutiny.